SG3 Management’s Amicus Therapeutics FOLD Stock Holding History

SG3 Management’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-15,000	Closed	-$161K	–	350
2022 Q2	$161K	Hold	15,000	–	–	0.02%	292
2022 Q1	$142K	Buy	+15,000	New	+$141K	﹤0.01%	810
2021 Q4	–	Sell	-24,700	Closed	-$236K	–	1126
2021 Q3	$236K	Sell	24,700 -300	-1%	-$3.07K	0.01%	751
2021 Q2	$241K	Sell	25,000 -65,000	-72%	-$634K	0.01%	790
2021 Q1	$889K	Sell	90,000 -187,500	-68%	-$2.9M	0.02%	634
2020 Q4	$6.41M	Buy	277,500 +277,200	+92,400%	+$5.67M	0.12%	157
2020 Q3	$4K	Sell	300 -189,700	-100%	-$2.76M	﹤0.01%	861
2020 Q2	$2.87M	Buy	+190,000	New	+$2.32M	0.2%	135

Other funds holding FOLD

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

SG3 Management's FOLD Position: Q1 2023 in Review

SG3 Management sold out of Amicus Therapeutics (FOLD) in Q1 2023, closing a stake of 2,500 shares — an estimated $30.5K sold.

SG3 Management first reported a position in FOLD in Q3 2020 and held it in 2 quarters. The position peaked at $212K in Q3 2020. 226 funds tracked by Wall St. Rank hold FOLD as of Q1 2023.

SG3 Management reported no remaining Amicus Therapeutics position as of Q1 2023 after selling out during the quarter.
SG3 Management sold 2,500 Amicus Therapeutics shares in Q1 2023, an estimated $30.5K.
SG3 Management first reported a position in Amicus Therapeutics in Q3 2020 and held it in 2 quarters.
SG3 Management's Amicus Therapeutics position peaked at $212K in Q3 2020.
226 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2023.

Based on SG3 Management's 13F filing for Q1 2023, filed 15 May 2023.